Mirtazapine protects against cisplatin‐induced oxidative stress and DNA damage in the rat brain. Issue 1 (21st December 2012)
- Record Type:
- Journal Article
- Title:
- Mirtazapine protects against cisplatin‐induced oxidative stress and DNA damage in the rat brain. Issue 1 (21st December 2012)
- Main Title:
- Mirtazapine protects against cisplatin‐induced oxidative stress and DNA damage in the rat brain
- Authors:
- Gulec, Mustafa
Oral, Elif
Dursun, Onur B.
Yucel, Atakan
Hacimuftuoglu, Ahmet
Akcay, Fatih
Suleyman, Halis - Abstract:
- <abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="pcn2395-sec-0001" sec-type="section"> <title>Aim</title> <p>Cisplatin chemotherapy is associated with neurotoxicity, and oxidative stress might play an important role in the pathogenesis. Mirtazapine may be a preventative agent via its less‐known antioxidant properties. The aim of this study was to examine the potential chemoprotective effects of mirtazapine against cisplatin‐induced oxidative stress and DNA damage.</p> </sec> <sec id="pcn2395-sec-0002" sec-type="section"> <title>Methods</title> <p>Twenty‐four rats were divided equally into four groups: control; cisplatin (10 mg/kg i.p.); cisplatin plus mirtazapine (10–30 mg/kg, respectively i.p and p.o.); and mirtazapine (30 mg/kg p.o.). The rats were killed at the end of the 14th day of treatment. Brain tissue was examined with regard to antioxidant/oxidant biochemical parameters.</p> </sec> <sec id="pcn2395-sec-0003" sec-type="section"> <title>Results</title> <p>Although glutathione (tGSH) and nitric oxide (NO) end product mean scores were found to be statistically higher in the control group when compared with the cisplatin group (72.44% and 61.99% percentage change [PC], respectively), malondialdehyde (MDA), myeloperoxidase (MPO), and 8‐hydroxyguanine (8‐OH‐GUA) mean scores were statistically lower in the control group in comparison with the cisplatin group (−55.48%, −67.99%, and −48.81% PC, respectively;<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="pcn2395-sec-0001" sec-type="section"> <title>Aim</title> <p>Cisplatin chemotherapy is associated with neurotoxicity, and oxidative stress might play an important role in the pathogenesis. Mirtazapine may be a preventative agent via its less‐known antioxidant properties. The aim of this study was to examine the potential chemoprotective effects of mirtazapine against cisplatin‐induced oxidative stress and DNA damage.</p> </sec> <sec id="pcn2395-sec-0002" sec-type="section"> <title>Methods</title> <p>Twenty‐four rats were divided equally into four groups: control; cisplatin (10 mg/kg i.p.); cisplatin plus mirtazapine (10–30 mg/kg, respectively i.p and p.o.); and mirtazapine (30 mg/kg p.o.). The rats were killed at the end of the 14th day of treatment. Brain tissue was examined with regard to antioxidant/oxidant biochemical parameters.</p> </sec> <sec id="pcn2395-sec-0003" sec-type="section"> <title>Results</title> <p>Although glutathione (tGSH) and nitric oxide (NO) end product mean scores were found to be statistically higher in the control group when compared with the cisplatin group (72.44% and 61.99% percentage change [PC], respectively), malondialdehyde (MDA), myeloperoxidase (MPO), and 8‐hydroxyguanine (8‐OH‐GUA) mean scores were statistically lower in the control group in comparison with the cisplatin group (−55.48%, −67.99%, and −48.81% PC, respectively; <italic>P</italic> &lt; 0.01). Finally, tGSH and NO end product levels were restored to normal (85.90% and 55.30% PC, respectively), and MDA, MPO, and 8‐OH‐GUA were significantly reduced by treatment with mirtazapine (−60.50%, −78.59%, and −38.10% PC, respectively; <italic>P</italic> &lt; 0.01).</p> </sec> <sec id="pcn2395-sec-0004" sec-type="section"> <title>Conclusion</title> <p>Mirtazapine has chemoprotective effects against cisplatin‐induced oxidative stress and DNA damage in the rat brain, which may be attributed to its antioxidant capabilities. It would be useful to investigate whether cisplatin at the desired doses can be given concurrently with mirtazapine.</p> </sec> </abstract> … (more)
- Is Part Of:
- Psychiatry and clinical neurosciences. Volume 67:Issue 1(2013)
- Journal:
- Psychiatry and clinical neurosciences
- Issue:
- Volume 67:Issue 1(2013)
- Issue Display:
- Volume 67, Issue 1 (2013)
- Year:
- 2013
- Volume:
- 67
- Issue:
- 1
- Issue Sort Value:
- 2013-0067-0001-0000
- Page Start:
- 50
- Page End:
- 58
- Publication Date:
- 2012-12-21
- Subjects:
- Psychiatry -- Periodicals
Neurology -- Periodicals
616.89 - Journal URLs:
- http://onlinelibrary.wiley.com/ ↗
- DOI:
- 10.1111/j.1440-1819.2012.02395.x ↗
- Languages:
- English
- ISSNs:
- 1323-1316
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6946.260550
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 3017.xml